Does liposome-encapsulated doxorubicin combined with cyclophosphamide reduce cardiotoxicity and preserve antitumor efficacy compared to conventional doxorubicin and cyclophosphamide in patients with metastatic breast cancer?
Liposome-encapsulated doxorubicin combined with cyclophosphamide offers a safer alternative to conventional doxorubicin for first-line metastatic breast cancer treatment by reducing cardiotoxicity without compromising efficacy.
Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
Batist et al. (Thu,) studied this question.